#USA #New York #Gross Law Firm #ESSA Pharma #EPIX Class Action

Take Action: Join the ESSA Pharma Class Action

In a significant move for shareholders, The Gross Law Firm has announced an urgent call for individuals who purchased shares of ESSA Pharma Inc. (NASDAQ: EPIX) during the specified class period to join a class action lawsuit. This announcement comes amid serious allegations that the company may have misled investors regarding the efficacy of its prostate cancer treatment delineated by the M-E Combination Study. The class period for the lawsuit covers from December 12, 2023, to October 31, 2024.

Why This Lawsuit Matters

The complaint asserts that during this period, ESSA Pharma's leaders provided materially false or misleading statements and failed to disclose crucial information. Specifically, the lawsuit contends that the drug masofaniten, when combined with enzalutamide, did not exhibit any clear benefits over the latter used alone, contrary to the representations made prior to and during the class period. This has raised significant concerns about the clinical and commercial prospects of masofaniten. Shareholders who feel they were deceived may be entitled to recover their losses from these misrepresentations.

Registration for the Class Action

To take part in this class action, shareholders must register by the March 25, 2025 deadline. Interested individuals can easily register their information through the dedicated form provided by the law firm. Once registered, shareholders will also gain access to a portfolio monitoring tool, ensuring they remain updated on the case's progress.

No Financial Obligation

It's important to note that registration incurs no cost or obligation for the participating shareholders. This opens a crucial window for those who believe they have been negatively impacted by the alleged actions of ESSA Pharma.

Why Choose The Gross Law Firm

The Gross Law Firm is renowned for its commitment to representing investors who have suffered losses due to corporate misconduct. The firm's mission centers on ensuring that companies adhere to ethical practices and prioritize transparent communication with their stakeholders. Their formidable reputation is built on their track record of holding corporations accountable for misleading their investors. They aim to assist plaintiffs in reclaiming part of their losses through this class action.

What to Expect Moving Forward

Once registered, shareholders will not only be able to follow the legal proceedings related to this lawsuit but also receive guidance on how to become a lead plaintiff if they choose to do so. A lead plaintiff status could empower individuals by granting them a more significant role throughout the litigation process.

Failure to act by the specified deadline could mean missing out on a chance to reclaim losses tied to the alleged misrepresentations of ESSA Pharma's executives. Given the serious allegations at hand, shareholders are encouraged to take prompt action to safeguard their rights.

How to Contact The Gross Law Firm

Shareholders seeking additional information can directly contact The Gross Law Firm through various options:

• - Website: Gross Law Firm
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

Located at 15 West 38th Street, 12th floor, New York, NY, the firm invites ESSA Pharma shareholders to join this important class action to help recover their investments and foster accountability in corporate governance. Don’t miss the opportunity to make your voice heard before the deadline expires.

Stay informed and protect your rights as an investor amidst the complexities of corporate renegotiations and potential compensations.